ALPROLIX: payments to doctors
Payments that named ALPROLIX as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $3.9M
- Providers
- 669
- Transactions
- 1,470
- Average per transaction
- $2,677
The per-transaction average — $2,677 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 669 providers the average total is $5,883, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Bioverativ Therapeutics Inc. | $3,429,944 | 87.1% |
| Sanofi | $438,565 | 11.1% |
| Sanofi-aventis U.S. LLC | $35,281 | 0.9% |
| Swedish Orphan Biovitrum AB | $32,004 | 0.8% |